This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

CardioNet, Inc. Reports Third Quarter 2012 Financial Results

CardioNet, Inc. (NASDAQ:BEAT), a leading wireless medical technology company with a current focus on the diagnosis and monitoring of cardiac arrhythmias, today reported results for the third quarter ended September 30, 2012.

Third Quarter 2012 Highlights
  • Completed acquisition of Cardiocore Lab, Inc., a leading research services business
  • Introduced CardioNet’s new wireless event device, wEvent
  • Generated positive adjusted EBITDA of $0.3 million in the third quarter 2012
  • Experienced increased patient volume year over year
  • Reduced DSO to 67 days, an 8 day improvement compared to year end 2011
  • $17.9 million in cash as of September 30, 2012

President and CEO Commentary

Joseph Capper, President and Chief Executive Officer of CardioNet, commented: “In August, we completed the acquisition of Cardiocore Lab, Inc. (“Cardiocore”), a leading cardiac core lab. This acquisition will enable us to leverage our strength in cardiac monitoring and the clinical superiority of our technology in a research setting. We believe the research market represents a significant growth opportunity for CardioNet and we are excited about the future potential.

“Also in the quarter, we introduced the wEvent to a select group of practices. This new wireless event monitor expands CardioNet’s portfolio by offering physicians an alternative to the traditional event monitor. With the full market release of the wEvent expected later this quarter, CardioNet now offers the most comprehensive suite of cardiac outpatient monitoring solutions in the industry.

“The progress that we have made on our strategic initiatives has had a positive impact on our third quarter results. For the quarter, we experienced positive adjusted EBITDA of $0.3 million, an improvement of $2.6 million over the prior year despite a challenging healthcare environment. This reflects our continued optimization of the patient services business in addition to an EBITDA benefit from the acquisition of Cardiocore.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.64 0.00%
FB $118.57 0.00%
GOOG $698.21 0.00%
TSLA $241.80 0.00%
YHOO $36.53 0.00%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs